TW341570B - Agent for potentiating nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof - Google Patents

Agent for potentiating nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof

Info

Publication number
TW341570B
TW341570B TW084111184A TW84111184A TW341570B TW 341570 B TW341570 B TW 341570B TW 084111184 A TW084111184 A TW 084111184A TW 84111184 A TW84111184 A TW 84111184A TW 341570 B TW341570 B TW 341570B
Authority
TW
Taiwan
Prior art keywords
group
substituted
unsubstituted
salt
phenyl
Prior art date
Application number
TW084111184A
Other languages
English (en)
Inventor
Tetsu Ono
Mutsuko Maekawa
Kazunari Hirata
Hirokazu Narita
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP6284273A external-priority patent/JPH08268883A/ja
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Application granted granted Critical
Publication of TW341570B publication Critical patent/TW341570B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW084111184A 1994-10-25 1995-10-23 Agent for potentiating nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof TW341570B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6284273A JPH08268883A (ja) 1994-10-25 1994-10-25 １−フェニル−１，２−エタンジオール誘導体またはそ の塩を含有する神経成長因子の作用増強剤
JP28427294 1994-10-25

Publications (1)

Publication Number Publication Date
TW341570B true TW341570B (en) 1998-10-01

Family

ID=26555404

Family Applications (1)

Application Number Title Priority Date Filing Date
TW084111184A TW341570B (en) 1994-10-25 1995-10-23 Agent for potentiating nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof

Country Status (16)

Country Link
US (6) US5807887A (zh)
EP (3) EP0790246B1 (zh)
JP (1) JP3218247B2 (zh)
KR (1) KR100447738B1 (zh)
AU (1) AU700561B2 (zh)
CA (1) CA2202032C (zh)
CZ (1) CZ293528B6 (zh)
DE (2) DE69531877T2 (zh)
DK (2) DK1020427T3 (zh)
ES (2) ES2208156T3 (zh)
HU (1) HU226980B1 (zh)
NZ (1) NZ294328A (zh)
PL (2) PL187004B1 (zh)
RO (1) RO119196B1 (zh)
TW (1) TW341570B (zh)
WO (1) WO1996012717A1 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100447738B1 (ko) * 1994-10-25 2005-09-20 도야마 가가쿠 고교 가부시키가이샤 1,2-에탄디올유도체또는그의염을함유한의약조성물
ZA973394B (en) * 1996-04-22 1997-11-20 Toyama Chemical Co Ltd Plaster containing 1,2-ethanediol derivative or a salt thereof.
AU1506499A (en) * 1997-12-12 1999-07-05 Toyama Chemical Co. Ltd. Alkyl ether derivatives or salts thereof and calcium antagonists containing the same
JP4549452B2 (ja) * 1997-12-12 2010-09-22 富山化学工業株式会社 アルキルエーテル誘導体またはその塩並びにそれらを含有するカルシウム拮抗剤
DK1186594T3 (da) * 1999-06-11 2009-09-14 Toyama Chemical Co Ltd N-alkoxylkyl-N,N-dialkylamin-derivater eller salte deraf og midler mod neurodegenerative sygdomme, som indeholder disse
AU9235101A (en) * 2000-10-10 2002-04-22 Toyama Chemical Co Ltd Remedies for retinal nerve diseases containing 1,2-ethanediol derivatives or salts thereof
HU230407B1 (hu) 2001-10-19 2016-04-28 Toyama Chemical Co., Ltd. Alkil-éter-származékok és sóik
MXPA04012534A (es) 2002-06-14 2005-04-19 Toyama Chemical Co Ltd Composicion farmaceutica para mejorar la funcion cerebral y metodo para mejorar la funcion cerebral.
EP2248899B8 (en) 2003-03-19 2015-07-15 Biogen MA Inc. NOGO receptor binding protein
US8486893B2 (en) 2004-06-24 2013-07-16 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
EP1904104B1 (en) 2005-07-08 2013-09-11 Biogen Idec MA Inc. Sp35 antibodies and uses thereof
JP2009544703A (ja) 2006-07-24 2009-12-17 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｐ３５またはＴｒｋＡアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法
JP5674469B2 (ja) * 2007-10-11 2015-02-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド ＬＩＮＧＯ−１アンタゴニストおよびＴｒｋＢアゴニストの投与を介して圧力誘導性の視神経障害を処置し、神経変性を防ぎ、ニューロン細胞の生存を促進する方法
US20110123553A1 (en) * 2007-11-08 2011-05-26 Biogen Idec Ma Inc. Use of LINGO-4 Antagonists in the Treatment of Conditions Involving Demyelination
AU2009269099B2 (en) 2008-07-09 2016-03-10 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
NZ702178A (en) 2012-05-14 2017-01-27 Biogen Ma Inc Lingo-2 antagonists for treatment of conditions involving motor neurons
EP3242893A1 (en) 2015-01-08 2017-11-15 Biogen MA Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894058A (en) * 1974-05-17 1975-07-08 Hoechst Co American Tetrahydrobenzofuranylphenoxypropylamines
US5254595A (en) * 1988-12-23 1993-10-19 Elf Sanofi Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
NZ232493A (en) * 1989-02-14 1992-06-25 Toyama Chemical Co Ltd Aryl- or heterocyclyl-substituted 1,2-ethanediol derivatives and pharmaceutical compositions
US5280032A (en) * 1989-02-14 1994-01-18 Toyama Chemical Co., Ltd. 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same
JP3044055B2 (ja) * 1990-08-09 2000-05-22 富山化学工業株式会社 １，２―エタンジオール誘導体およびその塩
JPH05230103A (ja) * 1992-02-18 1993-09-07 Taisho Pharmaceut Co Ltd ガングリオシド化合物
KR100447738B1 (ko) * 1994-10-25 2005-09-20 도야마 가가쿠 고교 가부시키가이샤 1,2-에탄디올유도체또는그의염을함유한의약조성물

Also Published As

Publication number Publication date
PL187490B1 (pl) 2004-07-30
RO119196B1 (ro) 2004-05-28
DE69525063D1 (de) 2002-02-21
AU700561B2 (en) 1999-01-07
US5968935A (en) 1999-10-19
US6034119A (en) 2000-03-07
WO1996012717A1 (fr) 1996-05-02
ES2208156T3 (es) 2004-06-16
EP0790246A4 (en) 1998-03-11
US5922721A (en) 1999-07-13
DK0790246T3 (da) 2002-03-18
CA2202032A1 (en) 1996-05-02
KR970707114A (ko) 1997-12-01
KR100447738B1 (ko) 2005-09-20
EP1020427A1 (en) 2000-07-19
US6103754A (en) 2000-08-15
PL187004B1 (pl) 2004-04-30
EP0790246A1 (en) 1997-08-20
HUT77361A (hu) 1998-03-30
US5932620A (en) 1999-08-03
ES2171559T3 (es) 2002-09-16
US5807887A (en) 1998-09-15
CZ293528B6 (cs) 2004-05-12
AU3709795A (en) 1996-05-15
DK1020427T3 (da) 2004-02-09
CA2202032C (en) 2009-06-16
DE69525063T2 (de) 2002-08-14
EP1020427B1 (en) 2003-10-01
DE69531877D1 (de) 2003-11-06
DE69531877T2 (de) 2004-07-29
CZ124997A3 (en) 1997-10-15
NZ294328A (en) 1998-06-26
EP1223169A1 (en) 2002-07-17
JP3218247B2 (ja) 2001-10-15
PL319940A1 (en) 1997-09-01
HU226980B1 (en) 2010-04-28
EP0790246B1 (en) 2002-01-16

Similar Documents

Publication Publication Date Title
TW341570B (en) Agent for potentiating nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof
MX9707879A (es) Derivados de piperazina sustituidos novedosos que tienen actividad antagonista de receptor de taquinina.
ATE294577T1 (de) Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen
HK1003708A1 (en) Peripheral vasodilating agent containing n-acylated 4-amino piperidine derivatives as active ingredients
BG103964A (en) SUBSTITUTED PYRAZOLS AS p38 KINASE INHIBITORS
CA2155673A1 (en) N-alkyl-2-substituted atp analogues
NO971471L (no) Nye karboksamider med fungicid aktivitet
ATE206611T1 (de) Verwendung von mangiferin oder seinen derivaten zur kosmetischen anwendung
CA2198238A1 (en) Piperidine derivatives as neurokinin antagonists
ATE225351T1 (de) Thienopyridin und thienopyrimidinderivate und ihre verwendung als entzündungshemmende mittel
PT889886E (pt) Novas fenantridinas substituidas na posicao 6
NZ233735A (en) Heterocyclic substituted aminophenol derivatives
FI952424A0 (fi) 11,21-bisfenyyli-19-norpregaanijohdannaisia
FR2651229B1 (fr) Nouveaux derives d'amino-acides, leur procede de preparation et leur application therapeutique.
MY104335A (en) 4-aminophridine deravatives
EP1103544A3 (en) Piperidine derivatives and antiplatelet agents containing the same
DE68918944T2 (de) Künstliche rezeptor-analoge.
MY132057A (en) Quinoxalinones, a process for their preparation and their use
MX9705649A (es) Compuestos de fenilo substituidos como antagonistas de endotelinas.
DK0873993T3 (da) Hidtil ukendte heterocykliske forbindelser, fremgangsmåde til deres fremstilling og sammensætninger indeholdende dem
TW326033B (en) Cyanobenzenesulfenyl halide and process for preparation of 3-substituted benzisothiazole using the same
BG101328A (en) New derivatives of imidazoloquinaxalon with heterocyclic substituents, their preparation and use
MY133140A (en) N-substituted azabicycloheptane derivatives, their preparation and use
AU3577295A (en) Reagent for the determination of free radicals
DK1042353T3 (da) 17-beta-aryl(arylmethyl)oxy(thio)alkylandrostanderivater